Tectonic Therapeutic, Inc.
TECXNasdaqHealthcare · Biological Products, (No Diagnostic Substances) · NY · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$84.0M | −$58.0M | −$44.6M | −$105.4M | −$118.8M | −$120.2M |
| Net income | −$74.2M | −$58.0M | −$42.8M | −$105.9M | −$119.1M | −$119.7M |
| Total assets | $261.0M | $152.9M | $39.4M | $103.9M | $203.8M | $271.2M |
| Total liabilities | $9.7M | $12.1M | $43.4M | $28.6M | $34.4M | $16.9M |
| Equity | $251.3M | $140.8M | −$84.6M | −$45.7M | $169.5M | $254.3M |
| EPS (diluted) | $-4.05 | $-6.83 | $-33.76 | $-2.42 | $-2.78 | — |
| Shares out. | 18.7M | 44.9M | 44.1M | 43.7M | 41.6M | 36.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −29.5%
- Return on assets
- −28.4%
- Return on capital (ROCE)
- −33.4%
- Liabilities / assets
- 3.7%
- Debt / equity
- 0.04×
- Book value / share
- $13.47
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 28.46safe
- Accruals / assets
- −5.4%clean
- Piotroski F-Score
- 5/7mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 warning● 3 good- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 2Recruitingreadout ~2026-10-09A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
- Phase 2Not Yet Recruitingreadout ~2027-11-21Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Tcg Crossover Gp Ii, LlcPassive (13G)Feb 27, 2026
- Aberdeen Group PlcPassive (13G)Jan 29, 2026
- Deep Track Capital, LpPassive (13G)Nov 14, 2025
- Ecor1 Capital, LlcPassive (13G)Nov 14, 2025
- Fmr LlcPassive (13G)May 12, 2025
- Springer Timothy AActivist (13D)Apr 7, 2025
- Mcguire TerranceActivist (13D)Apr 7, 2025
- Vida Ventures Ii, LlcActivist (13D)Apr 7, 2025
- Bml Investment Partners, L.P.Passive (13G)Feb 13, 2025
- Adar1 Partners, LpPassive (13G)Feb 23, 2024
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 2.6M | 10.2 | +6.5% |
| Apr 30, 2026 | 2.5M | 10.9 | +1.2% |
| Apr 15, 2026 | 2.4M | 13.6 | +0.5% |
| Mar 31, 2026 | 2.4M | 12.6 | -13.6% |
| Mar 13, 2026 | 2.8M | 6.0 | -9.6% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 7, 2026
- Director / officer change · Regulation FD disclosureApr 23, 2026
- Results of operationsFeb 26, 2026
- Director / officer change · Regulation FD disclosureFeb 24, 2026
- Results of operationsNov 6, 2025
- Other material eventOct 30, 2025
- Results of operations · Regulation FD disclosureAug 7, 2025
- Shareholder voteJun 6, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.